Editas Medicine
Stock
Stock
ISIN: US28106W1036
Ticker: EDIT
US28106W1036
EDIT
Price
Price
CHART BY
Frequently asked questions
What is Editas Medicine's market capitalization?
The market capitalization of Editas Medicine is $108.14M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Editas Medicine?
Editas Medicine's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$2.562. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Editas Medicine's stock?
Currently, 19 analysts cover Editas Medicine's stock, with a consensus target price of $5.167. Analyst ratings provide insights into the stock's expected performance.
What is Editas Medicine's revenue over the trailing twelve months?
Over the trailing twelve months, Editas Medicine reported a revenue of $61.76M.
What is the EBITDA for Editas Medicine?
Editas Medicine's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$222.63M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Editas Medicine?
Editas Medicine has a free cash flow of -$191.36M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Editas Medicine have, and what sector and industry does it belong to?
Editas Medicine employs approximately 265 people. It operates in the Health Care sector, specifically within the Biotechnology industry.
What is the free float of Editas Medicine's shares?
The free float of Editas Medicine is 81.78M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $108.14M
- EPS (TTM)
- -$2.562
- Free Float
- 81.78M
- Revenue (TTM)
- $61.76M
- EBITDA (TTM)
- -$222.63M
- Free Cashflow (TTM)
- -$191.36M
Pricing
- 1D span
- $1.306$1.375
- 52W span
- $1.28$11.58
Analyst Ratings
The price target is $5.167 and the stock is covered by 19 analysts.
Buy
5
Hold
12
Sell
2
Information
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
- Employees
- 265
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- ISIN
- US28106W1036
- Primary Ticker
- EDIT